LONG-TERM ADMINISTRATION OF TIANEPTINE IN DEPRESSED-PATIENTS AFTER ALCOHOL-WITHDRAWAL

被引:24
作者
MALKA, R
LOO, H
GANRY, H
SOUCHE, A
MAREY, C
KAMOUN, A
机构
[1] INST PSYCHIAT ROCHEFOUCAULT,PARIS,FRANCE
[2] INST RECH INT SERV,COURBEVOIE,FRANCE
[3] HOP MALEVOZ,MONTHEY,SWITZERLAND
[4] HOP ST ANNE,SERV HOSP UNIV SANTE MENTALE & THERAPEUT,F-75674 PARIS 14,FRANCE
关键词
D O I
10.1192/S0007125000296712
中图分类号
R749 [精神病学];
学科分类号
100205 ;
摘要
Alcohol interferes with the central metabolism of the catecholamines and especially with indolamines (5-HT). Thus, the use of an antidepressant such as tianeptine, whose main neurochemical effect is to increase the reuptake of 5-HT, seems to be particularly indicated for the continued treatment of depressed patients after alcohol withdrawal. This study evaluated the therapeutic efficacy and acceptability during long-term administration of tianeptine in depressed patients (major depressive episode or dysthymic disorder) in a multicentre trial, after withdrawal from alcohol abuse or dependence. The results relate to 1 30 depressed patients, who abstained from alcohol and received treatment for a year. Only one patient dropped-out because of side-effects, and medication was interrupted in 5% of subjects because of alcoholic relapses. Prescribed in the long term, tianeptine did not produce orthostatic hypotension, changes in bodyweight, or alterations in the ECG. All changes found in haematological and biochemical investigations suggested an improvement in patients' physical state. This, and other studies, indicate that tianeptine appears to have the potential to be a safe antidepressant, which might be particularly useful in those patients who are susceptible to the side-effects of psychotropic drugs.
引用
收藏
页码:66 / 71
页数:6
相关论文
共 39 条
[1]  
American Psychiatric Association, 1980, DIAGN STAT MAN MENT, V3rd
[2]   CONSENSUS CONFERENCE ON THE METHODOLOGY OF CLINICAL-TRIALS OF ANTIDEPRESSANTS, ZURICH, MARCH 1988 - REPORT OF THE CONSENSUS COMMITTEE [J].
ANGST, J ;
BECH, P ;
BOYER, P ;
BRUINVELS, J ;
ENGEL, R ;
HELMCHEN, H ;
HIPPIUS, H ;
LINGJAERDE, O ;
RACAGNI, G ;
SALETU, B ;
SEDVALL, G ;
SILVERSTONE, JT ;
STEFANIS, CN ;
STOLL, K ;
WOGGON, B .
PHARMACOPSYCHIATRY, 1989, 22 (01) :3-7
[3]   INHIBITION OF RAT-BRAIN TRYPTOPHAN-METABOLISM BY ETHANOL WITHDRAWAL AND POSSIBLE INVOLVEMENT OF THE ENHANCED LIVER TRYPTOPHAN-PYRROLASE ACTIVITY [J].
BADAWY, AAB ;
PUNJANI, NF ;
EVANS, CM ;
EVANS, M .
BIOCHEMICAL JOURNAL, 1980, 192 (02) :449-455
[4]  
BALLENGER JC, 1979, ARCH GEN PSYCHIAT, V36, P226
[5]  
BERSANI G, 1989, 37 C NAZ SOC IT PSIC, P1243
[6]  
DAVIS VE, 1967, J LAB CLIN MED, V69, P132
[7]  
DELALLEAU B, 1988, CLIN NEUROPHARMACOL, V11, pS83
[8]   HOPKINS SYMPTOM CHECKLIST (HSCL) - SELF-REPORT SYMPTOM INVENTORY [J].
DEROGATIS, LR ;
LIPMAN, RS ;
RICKELS, K ;
UHLENHUTH, EH ;
COVI, L .
BEHAVIORAL SCIENCE, 1974, 19 (01) :1-15
[9]  
DESIMONI MG, 1989, INT S SEROTONIN CELL, V87
[10]  
GALINOWKSI A, 1988, PSYCHOPHARMACOLOGY S, V96